Faculty Information - TAKADA Takuma

（Last updated : 2026-01-06 15:34:50）

TAKADA Takuma
Department Graduate School of Medical Science, Graduate School of Medical Science

Position

■ Published papers

1.	Original article	Functional analysis of human induced pluripotent stem cell-derived cardiac tissue during endothelial cell network changes 2025/12
2.	Original article	Low Body Weight and Long-term Outcomes in Patients with Venous Thromboembolism: Insights from the COMMAND VTE Registry-2. 2025/12
3.	Original article	Real-world management and outcomes of venous thromboembolism in patients with cancer and limited life expectancy in the direct oral anticoagulant era: insights from the COMMAND VTE Registry-2. 2025/12
4.	Original article	Concomitant Antiplatelet Therapy in Patients With Venous Thromboembolism Treated With Anticoagulants　- Insights From the COMMAND VTE Registry-2. 2025/11
5.	Original article	Extended anticoagulation therapy on clinical outcomes in patients with gastrointestinal cancer and isolated distal deep vein thrombosis: Insights from the ONCO DVT Study. 2025/11
6.	Original article	Prediction Score for Major Bleeding in Patients With Venous Thromboembolism Receiving Direct Oral Anticoagulants　- Insights From the COMMAND VTE Registry-2. 2025/11
7.	Original article	Impact of the Balloon Pulmonary Angioplasty on the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension: From the COMMAND VTE Registry-2. 2025/10
8.	Original article	The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study. 2025/10
9.	Original article	Impact of thrombocytopenia in patients with cancer-associated isolated distal deep vein thrombosis treated with edoxaban for 12 months versus 3 months: Insights from the ONCO DVT study. 2025/09
10.	Original article	Connexin 43 suppression enhances contractile force in human iPSC-derived cardiac tissues. 2025/08/08
11.	Original article	Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis. 2025/08
12.	Original article	Differences in risk factors between all-cause and pulmonary embolism-related death in acute pulmonary embolism: insights from the COMMAND VTE registry-2. 2025/07
13.	Original article	Edoxaban treatment without initial heparin lead-in for acute venous thromboembolism: insight from the COMMAND VTE registry-2. 2025/06
14.	Original article	D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis. 2025/05
15.	Original article	Correction: Predictors of the diuretic response in acute decompensated heart failure patients with severe aortic stenosis: sub-analysis of the LOHAS registry. 2025/03
16.	Original article	Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2. 2025/03
17.	Other	Reply to the Comments on “Cardiovascular Prognosis in Limb Ischemia Patients with Heart Failure and Systolic Dysfunction Following Major Amputation” 2025/02/18
18.	Original article	Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study. 2025/02
19.	Original article	Predictors of the diuretic response in acute decompensated heart failure patients with severe aortic stenosis: sub-analysis of the LOHAS registry. 2025/02
20.	Original article	Cardiovascular Prognosis in Limb Ischemia Patients With Heart Failure and Systolic Dysfunction Following Major Amputation. 2024/12/31
21.	Original article	Additional mineralocorticoid receptor antagonists in heart failure underdosed with guideline-directed medication 2024/12/19
22.	Original article	Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis. 2024/12
23.	Original article	Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism　- Insights From the COMMAND VTE Registry-2. 2024/12
24.	Original article	Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. 2024/12
25.	Original article	Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2. 2024/11
26.	Original article	Incidence and risk factors of ischemic stroke in patients with cancer-associated venous thromboembolism: from the Contemporary Management and Outcomes in Patients With Venous Thromboembolism Registry-2. 2024/11
27.	Original article	Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2. 2024/11
28.	Original article	Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). 2024/11
29.	Original article	Association Between White Blood Cell Counts at Diagnosis and Clinical Outcomes in Venous Thromboembolism　- From the COMMAND VTE Registry-2. 2024/10
30.	Original article	Initial anticoagulation therapy with single direct oral anticoagulant in patients with intermediate-high risk acute pulmonary embolism: From the COMMAND VTE Registry-2. 2024/10
31.	Original article	Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants. 2024/10
32.	Original article	Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban　- Insights From the ONCO DVT Study. 2024/09
33.	Original article	Prognostically Optimal Heart Rate at Discharge in Hospitalized Patients With Heart Failure and Atrial Fibrillation. 2024/08
34.	Original article	Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2. 2024/08
35.	Original article	Temporal Changes in Long-Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era. 2024/08
36.	Original article	External validation of the Pulmonary Embolism-Syncope, Anemia, and Renal Dysfunction bleeding score for early major bleeding in patients with acute pulmonary embolism: from the COMMAND VTE Registry-2. 2024/06
37.	Original article	Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2. 2024/05
38.	Original article	Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study. 2024/04
39.	Original article	Subclass phenotypes in patients with unprovoked venous thromboembolisms using a latent class analysis. 2024/04
40.	Original article	Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism　- A Predetermined Companion Report From the ONCO PE Trial. 2024/03
41.	Original article	The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study. 2024/03
42.	Original article	Cancer-associated venous thromboembolism in the direct oral anticoagulants era: Insight from the COMMAND VTE Registry-2 2024/02
43.	Original article	Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2. 2024/02
44.	Original article	Left Ventricular End-Systolic Diameter May Predict Persistent Heart Failure with Reduced Ejection Fraction. 2023/11
45.	Original article	Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. 2023/08
46.	Original article	Edoxaban for 12 Months Versus 3 Months in Patients With Cancer Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial. 2023/08
47.	Original article	Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level. 2023/02/15
48.	Original article	Prognostic impact of guideline-directed medical therapy in patients with heart failure on regular hemodialysis 2023/01/01
49.	Original article	Prognosis and diastolic dysfunction predictors in patients with heart failure and recovered ejection fraction. 2022/05/24
50.	Original article	Functional Evaluation of Human Bioengineered Cardiac Tissue Using iPS Cells Derived from a Patient with Lamin Variant Dilated Cardiomyopathy. 2022/03/30
51.	Original article	Impact of anatomical position of the inflow cannula on stroke in patients with left ventricular assist devices 2022/01
52.	Original article	Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contraction. 2021/12
53.	Original article	Nutritional status during hospitalization is associated with the long-term prognosis of patients with heart failure 2021/10/01
54.	Case report	Heart transplant candidate with medical complexity in the era of prolonged left ventricular assist device support — A case report 2020/10/22
55.	Original article	Effect of Transcatheter Aortic Valve Implantation on Renal Function in Patients With Chronic Kidney Disease. 2020/07/01
56.	Case report	Recurrent takotsubo syndrome with worsening of left ventricular outflow obstruction during haemodialysis: a case report. 2020/02/21
57.	Original article	Predictors of neo-aortic valve regurgitation in the long term after arterial switch operation 2020
58.	Original article	Impact of Late Ventricular Arrhythmias on Cardiac Mortality in Patients with Acute Myocardial Infarction 2019/07/08
59.	Original article	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. 2019/05
60.	Original article	Neoatherosclerosis 5 Years After Bioresorbable Vascular Scaffold Implantation. 2018/05
61.	Original article	The COFFEE Trial (COmparison of Fractional Flow Reserve Measurements through 4 FrEnch versus 6 FrEnch Diagnostic Catheter). 2018/02
62.	Case report	A case of Noonan syndrome found with syncope in adulthood. 2018
63.	Original article	Initial and Long-Term Results of a Microcatheter-Based Retrograde Approach for the Endovascular Treatment of Chronic Total Occlusion in Iliac or Femoropopliteal Arteries. 2017/05
64.	Other	Reply: Slender Sheaths Have the Potential to Expand the Use of Transradial Access for Complex CTO-PCI. 2017/05
65.	Original article	Transradial Coronary Interventions for Complex Chronic Total Occlusions. 2017/02
66.	Original article	Long-Term Outcomes of Successful Endovascular Therapy Via the Retrograde Approach for Below-the-Knee Chronic Total Occlusion in Patients With Critical Limb Ischemia After a Failed Antegrade Approach. 2017/01
67.	Case report	Persistent Bioresorbable Vascular Scaffold by Optical Coherence Tomography Imaging at 5 Years. 2017/01
68.	Original article	Long-term risks for patency loss in patients with hemodialysis after bare self-expandable nitinol stent implantation to femoropopliteal artery occlusive lesions. 2016/11
Display 5 items
Display all(68)

■ Academic conference presentation

1.	Alignment Control of Human iPSC-derived Cardiomyocytes, and the Role of FoxO1 Phosphorylation at Serine 284 by GSK-3β in the Heart. （Speech，Special/Invited Lecture） 2025/10/08
2.	Phosphorylation of FoxO1 at Serine 284 by GSK3β Is Essential for Maintaining Systolic Function in the Heart （Speech，General） 2025/07/31
3.	Phosphorylation of FoxO1 at Serine 284 by GSK3β Is Essential for Maintaining Systolic Function in the Heart （Poster notice，General） 2025/07/23
4.	Anemia Causes Poor Prognosis in Older Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction （Speech，Panelist at Symposium/Workshop (Appointed)） 2024/03/10
5.	Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Age: ONCO DVT Study （Speech，General） 2024/03/10
6.	Actual Management of Venous Thromboembolism in Patients with Terminal Cancer. From the COMMAND-VTE Registry-2 （Poster notice，General） 2024/03/09
7.	Clinical Characteristics and Impact of Bleeding Complications in Cancer-Related Isolated Distal Deep Vein Thrombosis: The ONCO DVT Study （Poster notice，General） 2024/03/09
8.	Direct Oral Anticoagulant-Associated Bleeding in Patients with Upper or Lower Gastrointestinal Cancer and Venous Thromboembolism: From the COMMAND VTE Registry-2 （Poster notice，General） 2024/03/09
9.	Optimal Discharge Heart Rate for Prognosis in Hospitalized HFpEF and HFrEF Patients with Persistent AF （Poster notice，General） 2024/03/09
10.	Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: ONCO DVT Study （Speech，General） 2024/03/08
11.	Fibroblasts Regulate Cardiomyocyte Alignment and Enable the Fabrication of 3D Cardiac Tissue with Layered Aligned Cardiomyocytes at Different Angles （Speech，General） 2024/03/08
12.	Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT Study （Speech，Panelist at Symposium/Workshop (Appointed)） 2024/03/08
13.	Preventive Effects of Gastric Antisecretory against Gastrointestinal Bleeding in Cancer Patients Treated with Edoxaban: Insight from the ONCO DVT Study （Speech，General） 2024/03/08
14.	Regulation of Connexin 43 in Human iPS Cell-derived Cardiomyocytes Affects the Contractility, but not Synchrony in the Cardiac Tissues （Speech，General） 2024/03/08
15.	Construction of three-dimensional iPS myocardial tissue by stacking oriented sheets （Speech，General） 2023/12/09
16.	Suppression of Connexin 43 in Human iPS cell-derived Cardiac Tissues Improves the Contractile Force through Promoting Cardiomyocytes Proliferation （Speech，General） 2023/12/09
17.	Fabrication of Quasi-isotropic Layered 3D Tissue by Aligned Human IPS Cell-derived Cardiomyocytes （Speech，General） 2023/12/02
18.	High rate of right ventricular pacing causes poor prognosis in patients with heart failure with preserved ejection fraction （Speech，General） 2023/10/06
19.	Optimizing Heart Rate Control at Discharge for Improved Prognosis in Hospitalized Patients with Heart Failure and Atrial Fibrillation （Speech，General） 2023/10/06
20.	Prognostic impact of anemia in elderly patients with hospitalized heart failure （Speech，Panelist at Symposium/Workshop (Appointed)） 2023/10/06
21.	Prognostically Optimal Heart Rate at Discharge in Hospitalized Patients with Heart Failure and Atrial Fibrillation （Speech，General） 2023/08/26
22.	Safety and effectiveness of initial high-dose anticoagulation therapy for cancer-associated venous thromboembolism in the real world: insight from the COMMAND VTE Registry-2 （Speech，General） 2023/08/25
23.	Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2 （Speech，General） 2023/08
24.	Clinical features and long-term outcomes of cancer-associated venous thromboembolism: transition from the warfarin era to the direct oral anticoagulant era （Speech，General） 2023/08
25.	Clinical features and long-term outcomes of venous thromboembolism in the warfarin era versus in the direct oral anticoagulant era （Speech，General） 2023/08
26.	Clinical long-term outcomes in fragile patients with venous thromboembolism receiving direct oral anticoagulant: From the COMMAND VTE Registry-2 （Speech，General） 2023/08
27.	Different impact of each score component in the simplified PESI score on acute mortality of patients with pulmonary embolism in the era of direct oral anticoagulant （Speech，General） 2023/08
28.	External validation of PE-SARD bleeding score for early major bleeding in patients with acute pulmonary embolism: Insight from the COMMAND VTE Registry-2 （Speech，General） 2023/08
29.	Initial anticoagulation therapy with direct oral anticoagulants in patients with intermediate-high-risk pulmonary embolism: from the COMMAND VTE Registry-2 （Speech，General） 2023/08
30.	The incidence and risk factors of newly-diagnosed cancer after diagnosis of venous thromboembolism: from the COMMAND VTE Registry-2 （Speech，General） 2023/08
31.	Alignment control of iPS cells-derived cardiomyocytes improve contractile properties of the entire cardiac tissue through each cardiomyocyte synchronous contraction （Poster notice，General） 2023/05/30
32.	Development of pulsatile human cardiac tissue with vascularization and helical structure for direct circulation support through perivascular transplantation （Speech，Panelist at Symposium/Workshop (Applied)） 2023/03/12
33.	Fibroblast alignment control regulates cardiomyocyte alignment in the bioengineered cardiac tissue （Speech，General） 2023/03/12
34.	Initial Anticoagulation Strategy in Pulmonary Embolism Patients with Right Ventricular Dysfunction and Elevated Troponin Levels: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/12
35.	Anticoagulation Strategies and Clinical Outcomes of Venous Thromboembolism in the Era of Direct Oral Anticoagulant: From the COMMAND VTE Registry-2 （Speech，Panelist at Symposium/Workshop (Appointed)） 2023/03/11
36.	Comparison of Clinical Characteristics and Outcomes of Venous Thromboembolism (VTE) between Young and Elder Patients: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/11
37.	Direct Oral Anticoagulants-Associated Bleeding Complications in Patients with Gastrointestinal Cancer and Venous Thromboembolism: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/11
38.	Influence of Fragility on Clinical Outcomes in Patients with Venous Thromboembolism and Direct Oral Anticoagulant: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/11
39.	Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients with Venous Thromboembolism: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/11
40.	Actual Management of Venous Thromboembolism Complicated by Antiphospholipid Antibody Syndrome in Japan. From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
41.	Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
42.	Clinical Characteristics, Anticoagulation Strategies and Outcomes Comparing Patients with and without History of Venous Thromboembolism: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
43.	How Does the Major Amputation Affect the Prognosis in CLTI Patients with Heart Failure? （Speech，Panelist at Symposium/Workshop (Appointed)） 2023/03/10
44.	Impact of Overexpression of GJA1 on Human iPS Cell-derived Cardiac Tissue with Disarray of Cardiomyocytes （Speech，General） 2023/03/10
45.	Risk Factor for Major Bleeding during Direct Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
46.	Risk Factors of Bleeding during Anticoagulation Therapy for Cancer-associated Venous Thromboembolism in the DOAC Era: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
47.	The Incidence of Occult Cancer after Diagnosis of Venous Thromboembolism in the Current Era: From the COMMAND VTE Registry-2 （Speech，General） 2023/03/10
48.	Utility and Application of Simplified PESI Score for Identification of Low-risk Patients with Pulmonary Embolism in the Era of DOAC （Speech，General） 2023/03/10
49.	Prognostic Impact of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure and Reduced Ejection Fraction on Regular Hemodialysis （Speech，Panelist at Symposium/Workshop (Appointed)） 2022/10/21
50.	Even moderate tricuspid regurgitation leads to a poor prognosis in hospitalized patients with heart failure and preserved ejection fraction （Poster notice，General） 2022/08/26
51.	New insights on the pathophysiology of non-genetic heart disease （Speech，Panelist at Symposium/Workshop (Appointed)） 2022/03/13
52.	Breakthroughs in the Pathophysiology and Treatment of HFpEF(Renin-angiotensin System Inhibitor Gives Lights on the Prognosis of HFpEF Patients if They Have Low Chloride Level) （Speech，Panelist at Symposium/Workshop (Appointed)） 2022/03
53.	Left Ventricular End-systolic Dimension can Predict Recovery of Left Ventricular Dysfunction among Patients with Heart Failure and Reduced Ejection Fraction （Speech，General） 2022/03
54.	Functional differences between the aligned and non-aligned human cardiac tissue （Speech，General） 2021/12/11
55.	Baseline QRS Duration >140 msec is Associated With Poor In-Hospital Prognosis of Patients With Acute Myocarditis （Poster notice，General） 2021/11/13
56.	Cardiomyocyte alignment control promotes the electrical integration and improve the contractile function of human cardiac tissue （Poster notice，General） 2021/11/13
57.	Alignment control of human induced pluripotent stem cell-derived cardiomyocytes promotes the synchronous cardiomyocyte contraction in the cardiac tissue （Poster notice，General） 2021/10/27
58.	Diastolic dysfunction at 1-year follow-up was associated with poor prognosis in patients with heart failure and recovered ejection fraction （Speech，General） 2021/10/02
59.	Prognostic Predictors of Patients with Acute Myocarditis -Multicenter Observational Study- （Speech，General） 2021/10/01
60.	Prognostic advantage of optimal medical therapy is NOT cancelled in hospitalized heart failure patients receiving regular hemodialysis （Poster notice，General） 2021/08/27
61.	Heart failure re-hospitalization differently affects the following mortality in patients with reduced, mid-range and preserved LVEF （Speech，General） 2021/08
62.	Low serum chloride level gives renin-angiotensin system inhibitor a prognostic impact in heart failure patients with preserved ejection fraction （Speech，General） 2021/08
63.	Aligned Human iPS cell-derived Cardiac Tissue Improves the Systolic and Relaxation Function through Promoting Synchronous Cardiomyocyte Contraction （Speech，General） 2021/03/26
64.	Improvable nutritional status during hospitalization is associated with long-term prognosis in hospitalized patients with heart failure （Speech，General） 2021/03/26
65.	Makoto Kishihara, Kentaro Jujo, Takuma Takada, Takuro Abe, Shota Shirotani, Nana Endo, Shonosuke Watanabe, Yuichiro Minami, Nobuhisa Hagiwara （Speech，General） 2021/03/26
66.	MitraClip For Severe Mitral Valve Regurgitation Increased Stroke Volume Compared To Surgical Repair Independent Of Left Ventricular Ejection Fraction （Speech，General） 2021/03/26
67.	機能性僧帽弁閉鎖不全症に対するMitraClipは左室駆出率にかかわらず、外科的修復に比べて一回拍出量を増加させる(MitraClip for Functional Mitral Valve Regurgitation Increased Stroke Volume Compared to Surgical Repair Independent of Left Ventricular Ejection Fraction) （Speech，General） 2021/03
68.	急性心筋炎後の左室収縮機能の回復を予測する因子　多施設共同観察研究(Predictors of Left Ventricular Systolic Functional Recovery after Acute Myocarditis: Multicenter Observational Study) （Speech，General） 2021/03
69.	Increase in Serum Chloride Level During Hospitalization Leads to Improved Clinical Outcomes in Patients With Heart Failure （Speech，General） 2020/11/13
70.	Predictors of Normalization of Left Ventricular Systolic Function After Acute Myocarditis -multicenter Observational Study （Speech，General） 2020/11/13
71.	Functional evaluation of aligned human iPS cell-derived cardiac tissue on micro-processed gel （Speech） 2020/09/27
72.	Preoperative Transaortic Pressure Gradient Predicts Renal Functional Improvement after Transcatheter Aortic Valve Implantation in Patients with Chronic Kidney Disease （Speech，General） 2020/07/27
73.	The Novel Strategy for Fabricating Aligned Human iPS Cell-derived Cardiac Tissue Model for Disease Research and Drug Development （Poster notice，General） 2020/07/27
74.	急性心筋梗塞患者における心室性不整脈の発現時期と予後の関係性(Relationship between the Timing of Ventricular Arrhythmia and Prognosis in Patients with Acute Myocardial Infarction) （Speech，General） 2018/03
75.	高度Killip分類の急性心筋梗塞患者における死亡の予測因子(Predictors of Death in Acute Myocardial Infarction Patients with High Killip Classes) （Speech，General） 2018/03
76.	左common trunkが長い患者に対する第2世代クライオバルーンを用いた非セグメント冷却アプローチ　施術所見と臨床転帰(Non-segmental Branch Freezes Approach for Patients with a Long Left Common Trunk Using Second-generation Cryoballoon: Procedural Findings and Clinical Outcome) （Speech，General） 2018/03
77.	早期、晩期および超晩期ステント血栓症患者における長期転帰の比較(Comparison of Long-term Outcomes among the Patients with Early, Late, and Very Late Stent Thrombosis) （Speech，General） 2018/03
78.	A New Technique for Box Isolation Using 2nd‒Generation Cryoballoon for Persistent Atrial Fibrillation （Speech，General） 2017/09/14
79.	Safety of Cryoballoon Ablation Compared with Radiofrequency Catheter Ablation for the Elderly Patients with Paroxysmal Atrial Fibrillation （Speech，General） 2017/09/14
80.	Everolimus溶出性生体吸収性血管スキャフォールドで治療された日本人患者の5年臨床転帰(Five-year Clinical Outcomes of Japanese Patients Treated with the Everolimus-Eluting Bioresorbable Vascular Scaffold) （Speech，General） 2017/03
81.	Primary PCI後の患者の心臓死亡率に対する遅発型心室性不整脈の影響(The Impact of Late Ventricular Arrhythmia on Cardiac Mortality in Patients After Primary Percutaneous Coronary Intervention) （Speech，General） 2017/03
82.	高齢心房細動患者に対する第2世代クライオバルーンアブレーションの安全性(Safety of Second-Generation Cryoballoon Ablation for the Elderly Patients with Atrial Fibrillation) （Speech，General） 2017/03
83.	持続性心房細動において肺静脈隔離術単独施行と比較した肺静脈隔離術後の連続的デフラグメンテーションアプローチにおける1年間フォローアップ転帰(1-year Follow-up Outcome of Sequential Defragmentation Approaches after Pulmonary-vein Isolation Compared to Only Pulmonary-vein Isolation in Persistent Atrial Fibrillation) （Speech，General） 2017/03
84.	重度大動脈弁狭窄患者の中等度冠動脈狭窄に対する瞬時血流予備量比の診断能(Diagnostic Performance of Instantaneous Wave Free Ratio for Intermediate Coronary Artery Stenosis in Patients with Severe Aortic Valve Stenosis) （Speech，General） 2017/03
85.	入院後7日未満で退院した急性心筋梗塞患者の予後(Prognosis of Acute Myocardial Infarction Patients Who Discharged from Hospital Earlier than Seven Days) （Speech，General） 2017/03
86.	My Most Memorable Bifurcation Case （Speech，General） 2016/06
87.	CHADS2スコアが高い患者において心房細動に対するアブレーション後に経口抗凝固療法を中断するリスクおよび安全性(The Risk and Safety of Discontinuing Oral Anticoagulation Therapy after Ablation for Atrial Fibrillation in Patients with High CHADS2 Score) （Speech，General） 2016/03
88.	Primary PCIによる治療を受けた急性心筋梗塞患者における慢性完全閉塞血行再建の予後への影響(The Prognostic Impact of Chronic Total Occlusion Revascularization in Patients with Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention) （Speech，General） 2016/03
89.	RAAS阻害薬は急性心筋梗塞後にβ遮断薬を服用中の患者の脳卒中を減らす(RAAS Inhibitor Reduces Stroke Following Acute Myocardial Infarction Patients Taking Β-blocker) （Speech，General） 2016/03
90.	ベアメタルステントを用いた経皮的冠動脈インターベンション後の非保護左冠動脈主幹部病変を有する患者の10年後の転帰(10-year Outcomes in Patients with Unprotected Left Main Coronary Artery Disease after Percutaneous Coronary Intervention with Bare Metal Stent) （Speech，General） 2016/03
91.	改変Jailedバルーン法　分岐部病変に対する経皮的冠動脈インターベンションに関連する側枝閉塞回避のための新規手技(Modified Jailed Balloon Technique: A Novel Technique to Avoid Side Branch Occlusion Regarding with Percutaneous Coronary Intervention for Bifurcation Lesions) （Poster notice，General） 2016/03
92.	急性心筋梗塞に対するprimary PCIを施行される患者における血清potassium濃度が心室性不整脈に与える影響(The Impact of Serum Potassium Level on Ventricular Arrhythmia in Patients Undergoing Primary Percutaneous Coronary Intervention with Acute Myocardial Infarction) （Speech，General） 2016/03
93.	浅大腿動脈病変に対する薬剤溶出ステント留置後の亜急性閉塞の臨床的影響(Clinical Impact of Subacute Occlusion Following Drug Eluting Stent Implantation for Superficial Femoral Artery Lesions) （Speech，General） 2016/03
94.	発作性心房細動に対するカテーテルアブレーション後の心拍変動は再発を予測する(Heart Rate Variability can Predict the Recurrence after Catheter Ablation for Paroxysmal Atrial Fibrillation) （Speech，General） 2016/03
Display 5 items
Display all(94)

■ Awards & honors

2020/10

第4回日本循環器学会基礎研究フォーラム（BCVR)　Encouragement Award

■ Education

1.	2019/04～2022/03	〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed, Doctor of Philosophy (Medicine)
2.	2006/04～2012/03	Osaka Medical College, Graduated, Doctor of Medicine